Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 232 entries
View as:

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Phase: N/A Priority: Normal
NCT ID: NCT01899105 Org: User:
Start: 07/31/13 End: 08/31/13 Due: 08/31/14

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT04786262 Org: User:
Start: 03/29/21 End: 06/30/30 Due: 06/30/31

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Phase: N/A Priority: Normal
NCT ID: NCT00627926 Org: User:
Start: 03/31/08 End: 05/31/10 Due: 05/31/11

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01768663 Org: User:
Start: 01/31/13 End: - Due: -

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01216046 Org: User:
Start: 10/31/10 End: 05/31/11 Due: 05/31/12

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06345755 Org: User:
Start: 04/17/24 End: 06/16/25 Due: 06/16/26

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01531673 Org: User:
Start: 02/29/12 End: 03/31/14 Due: 03/31/15

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Phase: N/A Priority: Normal
NCT ID: NCT06185764 Org: User:
Start: 02/20/24 End: 12/31/26 Due: 12/31/27

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03125395 Org: User:
Start: 05/12/17 End: 07/17/19 Due: 07/17/20

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03525574 Org: User:
Start: 10/09/18 End: 01/09/23 Due: 01/09/24

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Phase: N/A Priority: Normal
NCT ID: NCT00911963 Org: User:
Start: 04/30/09 End: 09/30/12 Due: 09/30/13

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

Phase: N/A Priority: Normal
NCT ID: NCT01060566 Org: User:
Start: 02/28/10 End: 04/30/10 Due: 04/30/11

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Phase: N/A Priority: Normal
NCT ID: NCT05643495 Org: User:
Start: 02/23/23 End: 08/19/24 Due: 08/19/25

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Phase: N/A Priority: Normal
NCT ID: NCT04058210 Org: User:
Start: - End: - Due: -

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02514473 Org: User:
Start: 07/31/15 End: 09/30/16 Due: 09/30/17

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03537651 Org: User:
Start: 04/25/18 End: 09/29/23 Due: 09/29/24

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Phase: N/A Priority: Normal
NCT ID: NCT04340362 Org: User:
Start: 06/08/20 End: 12/09/21 Due: 12/09/22

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01897233 Org: User:
Start: 07/31/13 End: 10/31/15 Due: 10/31/16

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00372385 Org: User:
Start: 08/31/06 End: 06/30/08 Due: 06/30/09

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00088504 Org: User:
Start: 07/31/04 End: 10/31/06 Due: 10/31/07

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00262483 Org: User:
Start: 12/31/05 End: 04/30/06 Due: 04/30/07

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00336479 Org: User:
Start: 06/30/06 End: 02/29/08 Due: 02/28/09

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02823470 Org: User:
Start: 06/30/16 End: 08/31/17 Due: 08/31/18

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01581138 Org: User:
Start: 07/31/12 End: 12/31/13 Due: 12/31/14

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Phase: N/A Priority: Normal
NCT ID: NCT03601637 Org: User:
Start: 09/07/18 End: 10/29/21 Due: 10/29/22